Eric Risberg / AP fileAn FDA advisory panel on Wednesday voted in favor of Gilead Sciences Inc's combination drug to reduce the risk of sexually acquired HIV infection in men and transgender women who have sex with men.
The treatment, Descovy, is a combination of emtricitabine and tenofovir alafenamide, and is already approved to treat chronic HIV. When asked to assess the efficacy of Descovy for pre-exposure prophylaxis of HIV in men and transgender women who have sex with men, a patient population that forms the largest component of the PrEP market, the panel voted 16-2 in favor.
Unfortunate name.
We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more:
Health Health Latest News, Health Health Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
FDA panel backs Gilead's HIV prevention drug Descovy, except in womenAn FDA advisory panel on Wednesday voted in favor of Gilead Sciences Inc's ... Blessed be the fruit Poor choice in business name Poor choice in headline. Women are not a tiny fraction of the world. Maybe 'but only for men' would be a better choice?
Source: Reuters - 🏆 2. / 97 Read more »
Patient groups push back against Gilead's pricey HIV prevention treatmentGilead Sciences Inc hopes to soon introduce a pricey new pill to prevent HIV in ... Gilead? For real? May the Lord Open. unfortunate name
Source: Reuters - 🏆 2. / 97 Read more »
FDA: Pricey Drug Approved on Manipulated DataApproval for a drug meant to treat children with a severe form of spinal muscular atrophy -- which costs over $2 million for a single treatment -- was based on manipulated data provided by the drug's maker, the FDA reports. Thx for giving tension and making me feel stupid }%** ! Whooops
Source: WebMD - 🏆 709. / 51 Read more »